Antiviral Drugs Market Analysis

Request Free Sample Copy

Report ID: 473
Published Date: Jun 06, 2025
Report Format: PDF, PPT

Buy Now

Antiviral Drugs Segmentation

Route of Administration (Oral, Injectable, Topical)

The oral segment is projected to dominate with the largest share of 57.5% in the antiviral drugs market by the end of 2037. The segment’s growth is highly driven by cost-effectiveness, patient compliance, and convenience. Oral antivirals such as hepatitis C DAAs and HIV protease inhibitors effectively constitute treatment protocols, owing to their established profiles, along with high bioavailability. As per the 2024 U.S. FDA report, more than 72% of the latest accepted antivirals are oral formulations, which positively reflects industry prioritization of remote dosage services, thereby suitable for the segment’s upliftment.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The hospital pharmacies segment is expected to hold the second-largest share of 39.2% in the antiviral drugs market by the end of the forecast timeline. This particular segment serves as the primary channel for catering to complicated therapies and acute treatments. In addition, the growth originates from inpatient demand for IV antivirals as well as specialty medications, including HCV/HIV regimens that require clinical observation. As per the 2024 CDC report, an estimated 66% of pandemic stockpile antivirals are supplied through hospital facilities that ensure fast deployment during outbreaks, thus denoting an optimistic outlook for the segment.

Our in-depth analysis of the global market includes the following segments:

Route of Administration	Oral Injectable Topical
Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies
Drug Class	Protease Inhibitors Polymerase Inhibitors Reverse Transcriptase Inhibitors Integrase Inhibitors
Indication	HIV/AIDS Hepatitis B C Influenza Herpes Simplex

Browse key industry insights with market data tables & charts from the report:

Antiviral Drugs Market Size & Share, Forecast Report 2037

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the antiviral drug market was over USD 63.1 billion.

The market size for the antiviral drug market is projected to reach USD 125.6 billion by the end of 2037 expanding at a CAGR of 7.3% during the forecast period i.e., between 2025-2037.

The major players in the market are AbbVie, Novartis, AstraZeneca, Johnson & Johnson, and others.

In terms of the route of administration segment, the oral segment is anticipated to garner the largest market share of 57.5% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 46.8% by the end of 2037 and provide more business opportunities in the future.